The Medicines Company Sustainability Profile
The Medicines Company, a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across major global markets. Founded in 1996, the company has made significant strides in developing innovative therapies, particularly in the fields of cardiovascular and infectious diseases. Renowned for its flagship product, inclisiran, The Medicines Company focuses on delivering unique solutions that address unmet medical needs. This groundbreaking treatment for hypercholesterolemia exemplifies the company's commitment to advancing patient care through cutting-edge science. With a strong market position, The Medicines Company has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its research capabilities. As a leader in the biopharmaceutical sector, the company continues to push the boundaries of medical innovation, striving to improve health outcomes worldwide.
DitchCarbon Score
How does The Medicines Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
The Medicines Company's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
The Medicines Company, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. However, it is important to note that The Medicines Company is a current subsidiary of Novartis AG, which provides emissions data and climate commitments through a cascading relationship. Novartis AG has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are aligned with the Science Based Targets initiative (SBTi) and are part of a broader strategy to achieve net-zero emissions by 2025 for Scope 1 and 2 emissions, while also addressing Scope 3 emissions in the supply chain. The Medicines Company benefits from Novartis's initiatives, including participation in the Carbon Disclosure Project (CDP) and the RE100 initiative, which aims for 100% renewable electricity. These commitments reflect a strong corporate responsibility towards climate action and sustainability. While specific reduction targets for The Medicines Company are not detailed, the overarching goals set by Novartis AG indicate a proactive approach to mitigating climate impact and enhancing environmental stewardship within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is The Medicines Company's Industry?
How Carbon Intensive is The Medicines Company's Location?
The Medicines Company's Scope 3 Categories Breakdown
The Medicines Company's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
The Medicines Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
The Medicines Company has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Taro Pharmaceutical Industries Ltd.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.